CSL is consolidating its R&D team in an effort to better position the organization “for long-term success in a rapidly evolving global environment.” The Australia-based biopharma and manufacturer is ...
CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine subsidiary in a wide-ranging restructure. The Melbourne-headquartered company will ...
SYDNEY--Vaccine and blood-products company CSL on Tuesday unveiled a sweeping corporate restructure that will include spinning off its flu-vaccine unit Seqirus and cutting up to 15% of its staff.
As CSL embarks on a restructuring drive to save more than $500 million annually over the next three years, the Australian company’s workforce reduction plans have reached one of its subsidiaries in ...
After gaining approvals in Japan, Europe and the U.K. for its hereditary angioedema (HAE) preventative treatment Andembry, CSL has scored a nod for the monoclonal antibody in the United States. With ...
Shares down 3.3%, face worst day since mid-Feb FY25 NPAT forecast below Visible Alpha consensus Final dividend of $1.45/share vs last year's $1.29 Aug 13 (Reuters) - Shares of CSL Ltd (CSL.AX), opens ...
MELBOURNE, Aug. 18, 2025 /PRNewswire/ -- Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant ...
SYDNEY--Vaccine and blood-products company CSL on Tuesday unveiled a sweeping corporate restructure that will include spinning off its flu-vaccine unit Seqirus and cutting up to 15% of its staff.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback